Andrews Medicine, Celltex partner for biotechnology, stem cell research in sports medicine
Click Here to Manage Email Alerts
Andrews Medicine and Celltex Therapeutics Corporation have announced the formation of Andrews Celltex Biologics, a new company focused on the development of biotechnology and stem cell research for the treatment of athletic injuries.
According to a press release, Andrews Celltex Biologics will be a jointly owned company between James R. Andrews, MD, chair and CEO of Andrews Medicine, and David G. Eller, chair and CEO of Celltex Therapeutics Corporation.
Andrews Celltex Biologics aims to explore the regenerative benefits of autologous mesenchymal stem cells (MSCs) for common sports injuries, according to the release.
“I have always known that stem cells, when properly handled, can add value to already effective treatments of inflammatory conditions caused by injury or disease,” Andrews said in the release.
“I am delighted that the FDA has been working with Celltex for studying the safety and efficacy of this combination of Celltex-produced MSCs with traditional medical treatment of multiple sports injury indications,” Andrews continued. “Our know-how and network of sports teams and physicians will add immediate value to our new joint company. I am convinced that Andrews Celltex Biologics will be a leader in this huge growth sector of health care coupled with regenerative medicine.”
Eller called the Andrews Medicine and Celltex Therapeutics Corporation partnership a “perfect match” in the release.
“Surgical treatments coupled with Celltex-produced regenerative MSCs will improve recovery time and remediation,” Eller said. “This joint effort of the two leading companies in their field will bring cutting edge regenerative health care for sports injuries and beyond.”
Click Here to Manage Email Alerts